The Dartmouth Institute

Featured

About Us

The Dartmouth Institute (TDI) convenes researchers, educators, and practitioners from multiple disciplines across Dartmouth to work toward our mission of improving population health, reducing health disparities, and creating high-performing, sustainable health systems. We are a foundational department within the Geisel School of Medicine at Dartmouth College with deep scholarly collaborations and practice innovation partnerships with Dartmouth Health. For more than 30 years, we have been dedicated to making health and healthcare better for everyone. Our research has increased the understanding of geographic variations in healthcare delivery, the adaptation and integration of payment reform models, and the factors influencing physician decision-making and patient-clinician communication. Since 2021, we have committed to using an equity lens in our research, education, and engagement work, with the explicit goal of focusing not just on unwarranted variation but on unjust variation, in order to support clinicians, policy makers, and systems leaders to develop and implement innovative new models of healthcare delivery to advance health equity.

Learn More

Our Priorities

The Dartmouth Institute helps clinicians, policy makers, and systems leaders improve practices and develop innovative new models of healthcare delivery. TDI’s strategic plan emphasizes a healthy and inclusive workplace community, impactful research that realizes concrete health policy and healthcare delivery outcomes, and excellence in teaching for Dartmouth students who are pursuing MS, MPH, MHA, MHCDS, and PhD degrees.

RSS Recent News

  • Why Young Men Are Killing Their Sperm—Vox June 2, 2026
    Read article—Features Ugis Gruntmanis, a professor of medicine, discussing the fertility risks associated with testosterone therapy amid rising use of the hormone among young men. Gruntmanis said that while testosterone can suppress sperm production, "the effect is reversible once patients stop taking testosterone," though it can take time for normal sperm production to return.
  • Landmark Cancer Trial Shows Success Against ‘Undruggable’ Cancer — Raising Hopes for Future Treatments—Nature June 2, 2026
    Read article—Features Michael Cole, a professor of molecular and systems biology, in an article on new approaches to targeting MYC, a cancer-driving protein long considered "undruggable." The article reports that Cole is investigating compounds that could block MYC's ability to activate genes involved in tumor growth following a breakthrough pancreatic cancer trial targeting RAS proteins.